Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Brain+

0.016

 

DKK

 

-10.34 %

Less than 1K followers

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.

Read more
Market cap
10.18M DKK
Turnover
41.32K DKK
Revenue
200K
EBIT %
-5,830 %
P/E
-
Dividend yield-%
-
Financial calendar
28/8
2025

Interim report Q2'25

All
Press releases
3rd party
ShowingAll content types
Regulatory press release6/10/2025, 7:58 AM

Brain+ A/S has received commitments to cover 100% of its TO 5 warrants, securing DKK 5.9 million in gross proceeds

Brain+
Press release6/6/2025, 2:56 PM

Invitation to investor webinar featuring Antony Hall: How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla

Brain+
Press release6/6/2025, 8:51 AM

New research underscores the effects of Cognitive Stimulation Therapy, supporting its role for UK care homes to comply with care quality statements

Brain+

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/5/2025, 9:49 AM

Brain+ signs agreement with UK care home group Majesticare deploying Ayla for effective dementia care

Brain+
Regulatory press release6/2/2025, 1:49 PM

Brain+ A/S announces the exercise price for its warrants of series TO 5

Brain+
Regulatory press release5/30/2025, 2:22 PM

Brain+ A/S - Minutes of Annual General Meeting

Brain+
Press release5/28/2025, 6:46 AM

Brain+ A/S: Leading UK dementia care authority, Antony Hall, joins Brain+ as Strategic Advisor

Brain+
Press release5/27/2025, 8:35 AM

Impala Nordic: Brain+ Podcast interview with Devika Wood, CEO

Brain+
Press release5/26/2025, 6:48 AM

Brain+ A/S: Brain+ signs its second UK sales agreement on Ayla with Park Homes UK Group

Brain+
Regulatory press release5/15/2025, 9:27 PM

Brain+ A/S convenes the Annual General Meeting for 2025

Brain+
Press release5/5/2025, 7:00 AM

Brain+ A/S: Brain+ selected for the NHS Dementia Innovators Programme in the UK

Brain+
Press release4/30/2025, 8:45 AM

Impala Nordic: Brain+ - Annual report interview with CEO, Devika Wood

Brain+
Regulatory press release4/29/2025, 6:19 PM

Brain+ A/S: Brain+ publishes its Annual Report for 2024

Brain+
Regulatory press release4/16/2025, 9:15 AM

Brain+ A/S: Brain+ appoints CCO Devika Wood as new CEO

Brain+
Regulatory press release4/9/2025, 6:50 AM

Brain+ A/S: Brain+ announces directed issue of units to convertible loan providers and guarantors

Brain+
Press release4/3/2025, 6:41 AM

Brain+ A/S: Contract signed with Copenhagen Municipality on extended and expanded access to Ayla

Brain+
Regulatory press release4/2/2025, 6:47 AM

Brain+ A/S: Brain+ announces outcome of unit rights issue

Brain+
Press release3/26/2025, 1:55 PM

Impala Nordic: Brain+ - Impala Nordic publishes teaser analysis

Brain+
Press release3/26/2025, 7:35 AM

Brain+ A/S informs of last day to subscribe in its ongoing rights issue of units

Brain+
Press release3/25/2025, 11:56 AM

Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group

Brain+
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team